Amgen expects "modest" effects on Epogen sales from Medicare dialysis payment rule
This article was originally published in Scrip
Executive Summary
A US Medicare proposed rule creating a bundled payment system for end-stage renal disease services would lead to only a modest reduction in use of Amgen's erythropoiesis-stimulating agent Epogen (epoetin-alfa), the company believes.